WILMINGTON, DE — Inhibikase Therapeutics Inc. (Nasdaq: IKT) reported a third-quarter net loss of $20.5 million, up from $11.9 million a year earlier, as increased research spending supported the global expansion of its Phase 3 clinical trial for a pulmonary arterial hypertension treatment.
The clinical-stage pharmaceutical company reported $193.3 million in cash, cash equivalents and marketable securities as of September 30, 2026, following a $50 million equity financing in July that strengthened its funding position as it advances its lead drug candidate, IKT-001.
Research and development expenses nearly doubled to $15 million from $7.6 million in the year-earlier quarter. Selling, general and administrative expenses increased to $7.2 million from $5.6 million.
The quarterly loss amounted to $0.10 per share, compared with $0.13 per share a year earlier.
For the first nine months of 2026, Inhibikase reported a net loss of $56.4 million, compared with $35.5 million during the same period in 2025. Research and development spending rose to $39.2 million from $23.4 million, while administrative expenses increased to $22.3 million from $16.8 million.
The company’s principal development program centers on IKT-001, an investigational once-daily oral treatment intended to address abnormal cell proliferation associated with pulmonary arterial hypertension, a disease characterized by elevated blood pressure in the arteries supplying the lungs.
Inhibikase said its global Phase 3 IMPROVE-PAH trial had obtained regulatory approvals in 28 countries as of November, with 79 of approximately 180 planned clinical sites activated.
The study uses a two-part adaptive design to evaluate the drug’s effects on pulmonary vascular resistance and patients’ exercise capacity.
Part A is a double-blind, placebo-controlled trial involving approximately 140 patients, with changes in pulmonary vascular resistance after 24 weeks serving as the primary endpoint.
Part B will evaluate approximately 346 patients using changes in six-minute walking distance at 24 weeks as its primary endpoint. The second portion is designed to begin after enrollment of the final patient in Part A.
An interim safety assessment involving 50 patients in Part A is expected during the first half of 2027.
“During our third quarter and in recent weeks we continued to advance our Phase 3 IMPROVE-PAH study, for which we have obtained 28 country regulatory approvals in the U.S. and E.U., with 79 clinical sites activated across a range of countries,” Chief Executive Officer Mark Iwicki said.
Inhibikase raised $50 million in gross proceeds in July through the sale of 25 million common shares to RA Capital Management using its at-the-market equity facility.
Later that month, 18.03 million of those shares were exchanged for pre-funded warrants to purchase common stock.
The company expects its available capital to support operations through the release of topline results from Part B of the Phase 3 trial, assuming the full and timely exercise of outstanding Series A and Series B warrants.
As of September 30, Inhibikase had approximately 140.3 million common shares and 60.6 million pre-funded warrants outstanding.
The company also received orphan drug designation from the U.S. Food and Drug Administration for IKT-001 in July. The designation provides potential development incentives, including certain tax credits, exemptions from specified regulatory fees and seven years of market exclusivity if the treatment receives approval.
Beyond its primary clinical trial, Inhibikase is evaluating whether IKT-001 could be used alongside sotatercept, another treatment targeting pulmonary arterial hypertension.
Additional nonclinical results supporting the proposed combination are expected beginning in the first quarter of 2027. The company has also initiated regulatory filings intended to support combination therapy within Part B of its Phase 3 program.
Inhibikase is conducting separate nonclinical research into potential applications for pulmonary hypertension associated with heart failure with preserved ejection fraction, including effects on myocardial fibrosis and diastolic function. Results are expected during 2027.
Another research program is examining the drug’s potential effects on pulmonary hypertension associated with interstitial lung disease, including vascular remodeling, right-heart function and fibrosis. Findings are expected in late 2027 or early 2028.
In October, the company appointed Scott M. Wasserman, chief medical officer of Kailera Therapeutics, to its board of directors. Wasserman is a cardiologist with more than two decades of experience in clinical development and pharmaceutical company leadership.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.
